Watch AYTU. Know when insiders buy.
One email the day a filing lands. Free.
AYTU
AYTU BIOPHARMA, INC
2.19
−0.02 −0.90%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · shorts 54
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $23.5MP/E —DIV YIELD —FCF YIELD 6.99%REV TTM $56.6M −14.0%NET INCOME −$34.1M −2177.8%NET CASH $11.7M52W 1.71 – 2.90SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Mar 31 | $12.4M | −32.7% | 61.2% | −$4.1M | −$5.6M | −240.7% | -0.53 | −$4.2M | $0 | −$4.2M | May 13 |
| Q2 2026 · Dec 31 | $15.2M | −6.5% | 63.5% | −$2M | −$10.6M | −1443.1% | -1.05 | $3.7M | $17K | $3.7M | May 13 |
| Q1 2026 · Sep 30 | $13.9M | −16.2% | 66.1% | −$1.5M | $2M | +33.3% | -0.08 | −$618K | $0 | −$618K | May 13 |
| Q4 2025 · Jun 30derived | $15.1M | +3.7% | 67.8% | −$7.6M | −$19.8M | — | -1.94 | $2.8M | $17K | $2.8M | Sep 23 |
| Q3 2025 · Mar 31 | $18.5M | +31.6% | 69.4% | $2.4M | $4M | — | 0.21 | −$6.5M | $69K | −$6.5M | May 13 |
| Q2 2025 · Dec 31 | $16.2M | −13.5% | 66.5% | −$1.7M | $788K | — | -0.26 | $2.9M | $6K | $2.9M | May 13 |
| Q1 2025 · Sep 30 | $16.6M | −7.0% | 72.3% | −$930K | $1.5M | — | -0.15 | −$1.2M | $136K | −$1.3M | May 13 |
| Q4 2024 · Jun 30derived | $14.6M | −52.5% | 75.7% | −$2.3M | −$4.6M | — | -0.82 | −$788K | $329K | −$1.1M | Sep 23 |
| Q3 2024 · Mar 31 | $14M | — | 73.9% | −$1.6M | −$2.9M | — | -0.52 | −$254K | $0 | −$254K | May 14 |
| Q2 2024 · Dec 31 | $18.7M | — | 77.9% | $3.1M | −$220K | — | -0.04 | −$135K | — | — | May 14 |
| Q1 2024 · Sep 30 | $17.8M | — | 73.2% | −$867K | −$8.1M | — | -1.48 | −$211K | — | — | May 14 |
| Q4 2023 · Jun 30derived | $30.7M | — | 60.4% | $169K | −$2.5M | — | -0.40 | $9.4M | — | — | Sep 26 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Jun 30 | $66.4M | 69.0% | −$7.8M | −$13.6M | -20.4% | -2.16 | −$1.9M | $228K | −$2.2M | — | — |
| FY2024 · to Jun 30 | $65.2M | 75.3% | −$1.6M | −$15.8M | -24.3% | -2.86 | −$1.4M | $329K | −$1.7M | — | — |
| FY2023 · to Jun 30 | $107.4M | 62.0% | −$17.1M | −$17.1M | -15.9% | -5.11 | −$5.1M | — | — | — | — |
| FY2022 · to Jun 30 | $96.7M | 54.1% | −$109.9M | −$108.8M | -112.5% | -74.01 | −$28.8M | $0 | −$28.8M | — | — |
| FY2021 · to Jun 30 | $65.6M | 44.5% | −$58.9M | −$58.3M | -88.8% | -3.48 | −$26M | $2.3M | −$28.3M | — | — |
| FY2020 · to Jun 30 | $27.6M | 70.0% | −$21.1M | −$13.6M | -49.3% | -3.01 | −$28.4M | $0 | −$28.4M | — | — |
Every number comes from AYTU BIOPHARMA, INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.